<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=10491412" created="10/07/2006" creator="Noriko Katsu"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>10491412</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term id="T1" lex="renal_cell_carcinoma-derived_ganglioside" sem="Organic_compound_other">Renal cell carcinoma-derived <term id="A2" lex="gangliosides" sem="Organic_compound_other">gangliosides</term></term> suppress <term id="T2" lex="nuclear_factor-kappaB_activation" sem="Other"><term id="T3" lex="nuclear_factor-kappaB" sem="Protein_complex">nuclear factor-kappaB</term> activation</term> in <term id="T4" lex="T_cell" sem="Cell_natural">T cells</term>.</sentence>
<event id="E1">
<type class="Metabolism"/>
<theme idref="A2"/>
<clue><clueLoc>Renal cell carcinoma</clueLoc>-<clueType>derived</clueType> gangliosides suppress nuclear factor-kappaB activation in T cells.</clue>
</event>
<event id="E2">
<type class="Negative_regulation"/>
<theme idref="E3"/>
<cause idref="E1"/>
<clue>Renal cell carcinoma-derived gangliosides <clueType>suppress</clueType> nuclear factor-kappaB activation in T cells.</clue>
</event>
<event KT="Other" id="E3">
<type class="Positive_regulation"/>
<theme idref="T3"/>
<clue>Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB <clueType>activation</clueType> <clueLoc>in T cells</clueLoc>.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">Activation of the <term id="T5" lex="transcription_factor_nuclear_factor-kappaB" sem="Protein_complex">transcription factor nuclear factor-kappaB</term> (<term id="T6" lex="NFkappaB" sem="Protein_complex">NFkappaB</term>) is impaired in <term id="T7" lex="T_cell" sem="Cell_natural">T cells</term> from <term id="T8" lex="patient" sem="Multicellular_organism_natural">patients</term> with <term id="T9" lex="renal_cell_carcinoma" sem="Tissue_natural">renal cell carcinomas</term> (<term id="T10" lex="RCC" sem="Tissue_natural">RCCs</term>).</sentence>
<event KT="Other" id="E4">
<type class="Positive_regulation"/>
<theme idref="T6"/>
<clue><clueType>Activation</clueType> <linkTheme>of</linkTheme> the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs).</clue>
</event>
<event KT="Fact" id="E5">
<type class="Negative_regulation"/>
<theme idref="E4"/>
<clue>Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is <clueType>impaired</clueType> <clueLoc>in T cells</clueLoc> from patients with renal cell carcinomas (RCCs).</clue>
</event>
<sentence id="S3">In circulating <term id="T11" lex="T_cell" sem="Cell_natural">T cells</term> from a subset of <term id="T12" lex="patient" sem="Multicellular_organism_natural">patients</term> with <term id="T13" lex="RCC" sem="Tissue_natural">RCCs</term>, the suppression of <term id="T14" lex="NFkappaB_binding_activity" sem="Other"><term id="T15" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> binding activity</term> is downstream from the <term id="T16" lex="stimulus-induced_degradation" sem="Other"><term id="A3" sem="Other">stimulus</term>-induced degradation</term> of the <term id="T17" lex="cytoplasmic_factor" sem="Protein_family_or_group">cytoplasmic factor</term> <term id="T18" lex="IkappaBalpha" sem="Protein_molecule">IkappaBalpha</term>.</sentence>
<event id="E6">
<type class="Cellular_physiological_process"/>
<theme idref="T11"/>
<clue>In <clueType>circulating</clueType> T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha.</clue>
</event>
<event id="E7">
<type class="Negative_regulation"/>
<theme idref="E8"/>
<clue><clueLoc>In circulating T cells</clueLoc> from a subset of patients with RCCs, the <clueType>suppression</clueType> <linkTheme>of</linkTheme> NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha.</clue>
</event>
<event KT="Other" id="E8">
<type class="Binding"/>
<theme idref="T15"/>
<clue>In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB <clueType>binding activity</clueType> is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha.</clue>
</event>
<event id="E9">
<type class="Protein_catabolism"/>
<theme idref="T18"/>
<clue>In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced <clueType>degradation</clueType> <linkTheme>of</linkTheme> the cytoplasmic factor IkappaBalpha.</clue>
</event>
<event id="E30">
<type class="Positive_regulation"/>
<theme idref="E9"/>
<cause idref="A3"/>
<clue>In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-<clueType>induced</clueType> degradation of the cytoplasmic factor IkappaBalpha.</clue>
</event>
<event id="E10">
<type class="Correlation"/>
<theme idref="E7"/>
<theme idref="E10"/>
<clue>In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is <clueType>downstream</clueType> <linkTheme>from</linkTheme> the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha.</clue>
</event>
<sentence id="S4"><term id="T19" lex="tumor-derived_soluble_product" sem="Organic_compound_other">Tumor-derived soluble products</term> from <term id="T20" lex="cultured_RCC" sem="Tissue_natural">cultured RCC</term> explants inhibit <term id="T21" lex="NFkappaB_activity" sem="Other"><term id="T22" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> activity</term> in <term id="T23" lex="T_cell" sem="Cell_natural">T cells</term> from <term id="T24" lex="healthy_volunteer" sem="Multicellular_organism_natural">healthy volunteers</term>, despite a normal level of <term id="T25" lex="stimulus-induced_IkappaBalpha_degradation" sem="Other"><term id="A4" sem="Other">stimulus</term>-induced <term id="T26" lex="IkappaBalpha" sem="Protein_molecule">IkappaBalpha</term> degradation</term> in these cells.</sentence>
<event id="E11">
<type class="Negative_regulation"/>
<theme idref="T22"/>
<cause idref="T19"/>
<clue>Tumor-derived soluble products from cultured RCC explants <clueType>inhibit</clueType> NFkappaB activity <clueLoc>in T cells from healthy volunteers</clueLoc>, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells.</clue>
<comment>NER: T19 sem mod, Protein_family_or_group -&gt; Other_oreganic_compound</comment></event>
<event KT="Other" id="E12">
<type class="Protein_catabolism"/>
<theme idref="T26"/>
<clue>Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha <clueType>degradation</clueType> <clueLoc>in these cells</clueLoc>.</clue>
</event>
<event KT="Other" id="E31">
<type class="Positive_regulation"/>
<theme idref="E12"/>
<cause idref="A4"/>
<clue>Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-<clueType>induced</clueType> IkappaBalpha degradation in these cells.</clue>
</event>
<event KT="Analysis" Polarity="Negative" assertion="non-exist" id="E13">
<type class="Negative_regulation"/>
<theme idref="E12"/>
<clue>Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a <clueType><clueKT><cluePolarity>normal</cluePolarity></clueKT> level</clueType> <linkTheme>of</linkTheme> stimulus-induced IkappaBalpha degradation in these cells.</clue>
</event>
<sentence id="S5">The inhibitory agent has several features characteristic of a <term id="T27" lex="ganglioside" sem="Organic_compound_other">ganglioside</term>, including sensitivity to <term id="T28" lex="neuraminidase" sem="Protein_molecule">neuraminidase</term> but not <term id="T29" lex="protease_treatment" sem="Other"><term id="T30" lex="protease" sem="Protein_family_or_group">protease</term> treatment</term>; <term id="T31" lex="hydrophobicity" sem="Other">hydrophobicity</term>; and molecular weight less than 3 kDa.</sentence>
<event id="E32">
<type class="Metabolism"/>
<theme idref="T19"/>
<clue><corefTheme>The inhibitory agent</corefTheme> has several features characteristic of a ganglioside, including <clueType>sensitivity</clueType> to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa.</clue>
</event>
<event id="E14">
<type class="Positive_regulation"/>
<theme idref="E32"/>
<theme idref="T28"/>
<clue>The inhibitory agent has several features characteristic of a ganglioside, including sensitivity <linkCause>to</linkCause> neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa.</clue>
</event>
<event id="E33">
<type class="Protein_metabolism"/>
<theme idref="T19"/>
<clue><corefTheme>The inhibitory agent</corefTheme> has several features characteristic of a ganglioside, including <clueType>sensitivity</clueType> to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa.</clue>
</event>
<event assertion="non-exist" id="E15">
<type class="Positive_regulation"/>
<theme idref="E33"/>
<theme idref="T28"/>
<clue>The inhibitory agent has several features characteristic of a ganglioside, including sensitivity <linkCause>to</linkCause> neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa.</clue>
</event>
<sentence id="S6">Indeed, we detected <term id="T32" lex="ganglioside" sem="Organic_compound_other">gangliosides</term> in supernatants from <term id="T33" lex="RCC_explant" sem="Cell_natural">RCC explants</term> and not from adjacent <term id="T34" lex="normal_kidney_tissue" sem="Tissue_natural">normal kidney tissue</term>.</sentence>
<sentence id="S7"><term id="T35" lex="ganglioside" sem="Organic_compound_other">Gangliosides</term> prepared from <term id="T36" lex="RCC_supernatant" sem="Cell_component">RCC supernatants</term>, as well as the <term id="T37" lex="purified_bovine_ganglioside" sem="Organic_compound_other">purified bovine <term id="T38" lex="ganglioside" sem="Organic_compound_other">gangliosides</term></term> <term id="A6" lex="G(m1)" sem="Organic_compound_other">G(m1)</term> and <term id="A7" lex="G(d1a)" sem="Organic_compound_other">G(d1a)</term>, suppressed <term id="T39" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> binding activity in <term id="T40" lex="T_cell" sem="Cell_natural">T cells</term> and reduced expression of the <term id="T41" lex="cytokine" sem="Protein_family_or_group">cytokines</term> <term id="T42" lex="IL-2" sem="Protein_molecule">IL-2</term> and <term id="T43" lex="IFN-gamma" sem="Protein_molecule">IFN-gamma</term>.</sentence>
<event KT="Other" id="E16">
<type class="Binding"/>
<theme idref="T39"/>
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB <clueType>binding activity</clueType> <clueLoc>in T cells</clueLoc> and reduced expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E17">
<type class="Negative_regulation"/>
<theme idref="E16"/>
<cause idref="T35"/>
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), <clueType>suppressed</clueType> NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E18">
<type class="Negative_regulation"/>
<theme idref="E16"/>
<cause idref="A6"/>
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), <clueType>suppressed</clueType> NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E19">
<type class="Negative_regulation"/>
<theme idref="E16"/>
<cause idref="A7"/>
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), <clueType>suppressed</clueType> NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E20">
<type class="Negative_regulation"/>
<theme idref="E26"/>
<cause idref="T35"/>
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and <clueType>reduced</clueType> expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E21">
<type class="Negative_regulation"/>
<theme idref="E26"/>
<cause idref="A6"/>
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and <clueType>reduced</clueType> expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E22">
<type class="Negative_regulation"/>
<theme idref="E26"/>
<cause idref="A7"/>
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and <clueType>reduced</clueType> expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E23">
<type class="Negative_regulation"/>
<theme idref="E27"/>
<cause idref="T35"/>
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and <clueType>reduced</clueType> expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E24">
<type class="Negative_regulation"/>
<theme idref="E27"/>
<cause idref="A6"/>
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and <clueType>reduced</clueType> expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E25">
<type class="Negative_regulation"/>
<theme idref="E27"/>
<cause idref="A7"/>
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and <clueType>reduced</clueType> expression of the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E26">
<type class="Gene_expression"/>
<theme idref="T42"/>
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced <clueType>expression</clueType> <linkTheme>of</linkTheme> the cytokines IL-2 and IFN-gamma.</clue>
</event>
<event id="E27">
<type class="Gene_expression"/>
<theme idref="T43"/>
<clue>Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced <clueType>expression</clueType> <linkTheme>of</linkTheme> the cytokines IL-2 and IFN-gamma.</clue>
</event>
<sentence id="S8">Taken together, our findings suggest that <term id="T44" lex="tumor-derived_ganglioside" sem="Organic_compound_other">tumor-derived <term id="T45" lex="ganglioside" sem="Organic_compound_other">gangliosides</term></term> may blunt <term id="T46" lex="antitumor_immune_response" sem="Other">antitumor immune responses</term> in <term id="T47" lex="patient" sem="Multicellular_organism_natural">patients</term> with <term id="T48" lex="RCC" sem="Tissue_natural">RCCs</term>.</sentence>
<event KT="Other" id="E28">
<type class="Metabolism"/>
<theme idref="T45"/>
<clue>Taken together, our findings suggest that <clueLoc>tumor</clueLoc>-<clueType>derived</clueType> gangliosides may blunt antitumor immune responses in patients with RCCs.</clue>
</event>
<event CL="L1" KT="Analysis" id="E29" uncertainty="probable">
<type class="Negative_regulation"/>
<theme idref="T46"/>
<cause idref="E28"/>
<clue>Taken together, our findings <clueKT>suggest</clueKT> that tumor-derived gangliosides <clueCL>may</clueCL> <clueType>blunt</clueType> antitumor immune responses in patients with RCCs.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
